MXPA05001277A - 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. - Google Patents
2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.Info
- Publication number
- MXPA05001277A MXPA05001277A MXPA05001277A MXPA05001277A MXPA05001277A MX PA05001277 A MXPA05001277 A MX PA05001277A MX PA05001277 A MXPA05001277 A MX PA05001277A MX PA05001277 A MXPA05001277 A MX PA05001277A MX PA05001277 A MXPA05001277 A MX PA05001277A
- Authority
- MX
- Mexico
- Prior art keywords
- aminoaryl
- thiazoles
- aryl
- amino
- kit inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
La presente invencion se refiere a compuestos novedosos seleccionados de 2-(3-aminoaril)amino-4-aril-tiazoles de formula (1) que modulan, regulan, y/o inhiben selectivamente las transducciones de senal mediadas por ciertas tirosina cinasas nativas y/o mutantes implicadas en una variedad de enfermedades de humano o animal tales como trastornos proliferativos celulares, metabolicos, alergicos, y degenerativos; mas particularmente, estos compuestos son inhibidores del c-kit potentes y selectivos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40006402P | 2002-08-02 | 2002-08-02 | |
PCT/IB2003/003685 WO2004014903A1 (en) | 2002-08-02 | 2003-07-31 | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05001277A true MXPA05001277A (es) | 2005-10-06 |
Family
ID=31715693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05001277A MXPA05001277A (es) | 2002-08-02 | 2003-07-31 | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
Country Status (20)
Country | Link |
---|---|
US (5) | US20050239852A1 (es) |
EP (1) | EP1525200B1 (es) |
JP (1) | JP4726486B2 (es) |
KR (1) | KR101036866B1 (es) |
CN (1) | CN100491374C (es) |
AT (1) | ATE375342T1 (es) |
BR (1) | BRPI0313165B8 (es) |
CA (1) | CA2494695C (es) |
CY (1) | CY1107036T1 (es) |
DE (1) | DE60316810T2 (es) |
DK (1) | DK1525200T3 (es) |
ES (1) | ES2294344T3 (es) |
HK (1) | HK1084382A1 (es) |
IL (1) | IL166528A0 (es) |
MX (1) | MXPA05001277A (es) |
NO (1) | NO330608B1 (es) |
NZ (1) | NZ538490A (es) |
PT (1) | PT1525200E (es) |
WO (1) | WO2004014903A1 (es) |
ZA (1) | ZA200501331B (es) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE408387T1 (de) | 2001-03-08 | 2008-10-15 | Univ Pennsylvania | Faciale amphiphile polymere als antiinfektiöse mittel |
CA2452368A1 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
ATE330608T1 (de) | 2001-06-29 | 2006-07-15 | Ab Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
WO2003002106A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitions for treating allergic diseases |
JP3836019B2 (ja) * | 2001-11-21 | 2006-10-18 | 松下電器産業株式会社 | 受信装置、送信装置及び送信方法 |
US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
CA2494695C (en) * | 2002-08-02 | 2011-04-05 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US20080025916A1 (en) * | 2003-02-27 | 2008-01-31 | Ab Science | Tailored Treatment Suitable for Different Forms of Mastocytosis |
JP2006521355A (ja) | 2003-03-17 | 2006-09-21 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア・センター・フオー・テクノロジー・トランスフアー | 表面的に両親媒性のポリマー及びオリゴマーならびにそれらの使用 |
WO2004096225A2 (en) * | 2003-04-28 | 2004-11-11 | Ab Science | Use of tyrosine kinase inhibitors for treating cerebral ischemia |
ATE395052T1 (de) * | 2003-08-15 | 2008-05-15 | Ab Science | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes |
PL1702917T3 (pl) * | 2003-12-25 | 2018-02-28 | Nippon Shinyaku Co., Ltd. | Pochodna amidowa i lek |
US8222456B2 (en) | 2004-01-23 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof |
BRPI0507271A (pt) * | 2004-01-30 | 2007-06-26 | Ab Science | 2-(3-substituìda-aril)amino-4-aril-tiazóis como inibidores de tirosina cinase |
KR20070011458A (ko) | 2004-04-08 | 2007-01-24 | 탈자진 인코포레이티드 | 키나제의 벤조트리아진 억제제 |
WO2005102318A1 (en) * | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
US20080146585A1 (en) * | 2004-04-20 | 2008-06-19 | Ab Science | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy |
JP2007533732A (ja) * | 2004-04-23 | 2007-11-22 | アブ サイエンス | 線維症を処置するためのc−kit阻害剤の使用法 |
WO2005102326A2 (en) * | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating renal diseases |
RU2379298C2 (ru) * | 2004-05-17 | 2010-01-20 | Оцука Фармасьютикал Ко., Лтд. | Соединение тиазола и его применение |
WO2005112920A1 (en) * | 2004-05-18 | 2005-12-01 | Ab Science | Use of mast cells inhibitors for treating patients exposed to chemical or biological weapons |
WO2005115304A2 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
MX2007002208A (es) | 2004-08-25 | 2007-05-08 | Targegen Inc | Compuestos hetrociclicos y metodos de uso. |
US20060241052A1 (en) * | 2005-02-25 | 2006-10-26 | Degrado William F | Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer |
UA92746C2 (en) | 2005-05-09 | 2010-12-10 | Акилайон Фармасьютикалз, Инк. | Thiazole compounds and methods of use |
WO2007037898A2 (en) * | 2005-08-29 | 2007-04-05 | Housey Pharmaceuticals Inc | Theramutein modulators |
MX2007008848A (es) * | 2005-06-08 | 2008-04-16 | Targegen Inc | Metodos y composiciones para el tratamiento de desordenes oculares. |
GB0512091D0 (en) * | 2005-06-14 | 2005-07-20 | Novartis Ag | Organic compounds |
WO2007026251A2 (en) * | 2005-07-14 | 2007-03-08 | Ab Science | Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
RU2597364C2 (ru) | 2005-11-01 | 2016-09-10 | Таргеджен, Инк. | Би-арил-мета-пиримидиновые ингибиторы киназ |
KR100716891B1 (ko) * | 2005-11-01 | 2007-05-09 | (주)아모레퍼시픽 | 피리딘 티아졸 카복사마이드 유도체, 이의 제조방법 및이를 함유하는 피부 미백용 조성물 |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US20070149508A1 (en) * | 2005-11-02 | 2007-06-28 | Targegen, Inc. | Six membered heteroaromatic inhibitors targeting resistant kinase mutations |
US20070135368A1 (en) * | 2005-12-09 | 2007-06-14 | Knapp Pamela E | Cell-to-cell transmission of siRNA induced gene silencing in mammalian cells |
WO2007076460A2 (en) * | 2005-12-23 | 2007-07-05 | Kalypsys, Inc. | Substituted thiazole ureas useful as inhibitors of protein kinases |
DE102005062986A1 (de) * | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
DE102005062990A1 (de) | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln |
ES2458291T3 (es) * | 2006-04-20 | 2014-04-30 | Janssen Pharmaceutica Nv | Derivados de amidas aromáticas como inhibidores de la cinasa C-KIT |
WO2008008234A1 (en) | 2006-07-07 | 2008-01-17 | Targegen, Inc. | 2-amino-5-substituted pyrimidine inhibitors |
US8227470B2 (en) | 2007-01-12 | 2012-07-24 | Ab Science | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors |
US9187485B2 (en) | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
US8153792B2 (en) | 2007-02-13 | 2012-04-10 | Ab Science | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors |
EP1964848A1 (en) * | 2007-03-01 | 2008-09-03 | Bayer Schering Pharma Aktiengesellschaft | Radiofluorination methods |
JP2010528019A (ja) | 2007-05-22 | 2010-08-19 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ヘテロアリール置換チアゾール |
KR100885692B1 (ko) * | 2007-06-12 | 2009-02-26 | 한국화학연구원 | 2-(3-클로로-4-메톡시)아닐리노-4-아릴싸이아졸 유도체또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및이를 유효성분으로 함유하는 암 예방 및 치료용 약학적조성물 |
CA2704199C (en) * | 2007-11-01 | 2016-01-19 | Acucela Inc. | Amine derivative compounds for treating ophthalmic diseases and disorders |
FR2928150A1 (fr) * | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
EP2145891A1 (en) * | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
JP5734953B2 (ja) * | 2009-04-06 | 2015-06-17 | ニューロテック ファーマシューティカルズ カンパニー リミテッドNeurotech Pharmaceuticals Co.,Ltd. | やけどによる損傷の治療または予防用薬学的組成物 |
US20120302577A1 (en) * | 2010-01-28 | 2012-11-29 | Ab Science | Treatment of gist with masitinib |
AR080096A1 (es) | 2010-02-01 | 2012-03-14 | Ab Science | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib |
AR080380A1 (es) * | 2010-03-09 | 2012-04-04 | Ab Science | Tratamiento de la demencia tipo alzheimer con masitinib |
DE102010012594A1 (de) * | 2010-03-23 | 2011-09-29 | Beiersdorf Ag | Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Thiazolderivaten |
AR080933A1 (es) | 2010-04-20 | 2012-05-16 | Ab Science | Tratamiento de esclerosis multiple con masitinib |
US20130267484A1 (en) * | 2010-06-02 | 2013-10-10 | Ab Science | Treatment of rheumatoid arthritis with masitinib |
US10045978B2 (en) | 2010-11-05 | 2018-08-14 | Ab Science | Treatment of mastocytosis with masitinib |
US20140147415A1 (en) * | 2010-11-05 | 2014-05-29 | Ab Science | Treatment of mastocytosis with masitinib |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
US9078894B2 (en) * | 2011-02-04 | 2015-07-14 | Ab Science | Treatment of severe persistant asthma with masitinib |
CN103402522A (zh) * | 2011-03-01 | 2013-11-20 | 恩法玛康有限责任公司 | N-(4-甲氧基苯基)-1-苯基-1h-吡唑-3-胺及相关化合物的用途 |
US20140051662A1 (en) | 2011-04-08 | 2014-02-20 | Ab Science | Treatment of multiple myeloma with masitinib |
US9168245B2 (en) * | 2011-07-27 | 2015-10-27 | Ab Science | Selective protein kinase inhibitors |
CN103130792B (zh) * | 2011-11-30 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种2-氨基噻唑类化合物 |
CN103130791B (zh) * | 2011-11-30 | 2016-05-04 | 正大天晴药业集团股份有限公司 | 一种新型苯甲酰胺类化合物 |
AU2013326463B2 (en) | 2012-10-04 | 2018-01-18 | Ab Science | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
TW201534597A (zh) * | 2013-06-20 | 2015-09-16 | Ab Science | 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物 |
USD704961S1 (en) | 2013-07-03 | 2014-05-20 | Wearwell | Studded molded mat |
TW201605449A (zh) | 2013-12-02 | 2016-02-16 | Ab化學公司 | 馬賽替尼治療結腸直腸癌的用途 |
EP2886543A1 (en) | 2013-12-18 | 2015-06-24 | Sandoz Ag | Crystalline form of mastinib mesylate |
US20170196853A1 (en) | 2014-06-02 | 2017-07-13 | Ab Science | Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer |
CN104045632B (zh) * | 2014-06-03 | 2016-09-07 | 辽宁大学 | 抗肿瘤药物苯并二氢吡喃(噻喃)酰胺类化合物及其药学上可接受的盐及制备方法和应用 |
US20160175302A1 (en) * | 2014-12-17 | 2016-06-23 | Ab Science | Masitinib for treating gastric cancer |
ES2796276T3 (es) * | 2015-02-05 | 2020-11-26 | Ab Science | Compuestos con actividad antitumoral |
WO2017016512A1 (zh) * | 2015-07-29 | 2017-02-02 | 苏州晶云药物科技有限公司 | 马赛替尼甲磺酸盐的新晶型及其制备方法 |
JP6801892B2 (ja) | 2015-10-05 | 2020-12-16 | エービー サイエンス | マシチニブによる重度の全身性肥満細胞症の治療 |
DK3240538T3 (da) | 2016-03-25 | 2021-12-06 | Ab Science | Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose |
WO2018177854A1 (en) | 2017-03-31 | 2018-10-04 | Sandoz Ag | Crystalline form of masitinib |
CN108721283A (zh) * | 2017-04-20 | 2018-11-02 | 华东理工大学 | 噻唑衍生物在治疗非淋巴细胞性白血病中的应用 |
CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
EP4061371A1 (en) | 2019-11-22 | 2022-09-28 | AB Science | Masitinib for the treatment of sickle cell disease |
EP3831384A1 (en) | 2019-12-02 | 2021-06-09 | AB Science | Use of masitinib for the treatment of eosinophilic asthma |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
JP2023515429A (ja) | 2020-02-20 | 2023-04-13 | エービー サイエンス | 多発性硬化症患者の亜集団の処置のためのマシチニブ |
EP4132528A1 (en) | 2020-04-10 | 2023-02-15 | AB Science | Use of masitinib for the treatment of coronavirus disease 2019 (covid-19) |
CA3201259A1 (en) | 2020-12-16 | 2022-06-23 | Alain Moussy | Masitinib for the treatment of alzheimer's disease |
EP4175639B1 (en) | 2021-05-17 | 2023-10-25 | AB Science | Masitinib for the treatment of castrate-resistant prostate cancer |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
CN114644582B (zh) * | 2022-04-11 | 2024-03-29 | 中原工学院 | 一种苯基双硫脲类化合物的制备方法 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US590622A (en) * | 1897-09-28 | Edward mcconnell | ||
US3201409A (en) * | 1961-04-24 | 1965-08-17 | John D Spivack | 2-substituted aminothiazoles |
US3467666A (en) * | 1966-11-07 | 1969-09-16 | Geigy Chem Corp | 2-substituted aminothiazoles |
US3740420A (en) * | 1967-11-28 | 1973-06-19 | Crown Zellerbach Corp | Pharmaceutical compositions with dimethyl sulfoxide |
FR2077803B1 (es) * | 1970-02-16 | 1973-03-16 | Innothera Lab Sa | |
US3743727A (en) * | 1970-11-16 | 1973-07-03 | Crown Zellerbach Corp | Enhancing tissue penetration of certain antimicrobial agents with dimethyl sulfoxide |
US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
US3989816A (en) * | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
CA1163561A (en) * | 1979-11-06 | 1984-03-13 | Cyril Boroda | Preparation containing nitroglycerine and optionally other medicaments and preparation thereof |
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
US4411893A (en) * | 1981-08-14 | 1983-10-25 | Minnesota Mining And Manufacturing Company | Topical medicament preparations |
JPS5968336U (ja) | 1982-10-28 | 1984-05-09 | シャープ株式会社 | 原稿カバ−開閉検出装置 |
CA1236029A (en) * | 1984-05-14 | 1988-05-03 | Edmund Sandborn | Pharmaceutical solutions comprising dimethyl sulfoxide |
US4615699A (en) * | 1985-05-03 | 1986-10-07 | Alza Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
JPS6328447A (ja) | 1986-07-21 | 1988-02-06 | Toshiba Corp | 加速管 |
JP2752361B2 (ja) | 1986-11-03 | 1998-05-18 | エバレディー、バッテリー、カンパニー、インコーポレーテッド | 正極端子ピンと過塩素酸塩電解質を有する密閉された非水性電池 |
US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
DE3815221C2 (de) * | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
GB9413975D0 (en) * | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
ATE114661T1 (de) | 1990-04-02 | 1994-12-15 | Pfizer | Benzylphosphonsäure-tyrosinkinaseinhibitoren. |
US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
ATE159009T1 (de) | 1991-05-10 | 1997-10-15 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
JP2549583B2 (ja) | 1991-05-10 | 1996-10-30 | 明成化学工業株式会社 | セルロース繊維の反応染色における未固着染料の退色防止法 |
US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
JPH06503095A (ja) | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
TW225528B (es) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
JPH08503450A (ja) | 1992-08-06 | 1996-04-16 | ワーナー−ランバート・コンパニー | 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する2−チオインドール(セレノインドール)および関連ジスルフィド(セレニド) |
US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
US5656643A (en) * | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US6239172B1 (en) * | 1997-04-10 | 2001-05-29 | Nitrosystems, Inc. | Formulations for treating disease and methods of using same |
JP3728770B2 (ja) | 1995-06-01 | 2005-12-21 | ブラザー工業株式会社 | 原稿読取り装置 |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5906202A (en) | 1996-11-21 | 1999-05-25 | Aradigm Corporation | Device and method for directing aerosolized mist to a specific area of the respiratory tract |
US5776020A (en) * | 1997-05-19 | 1998-07-07 | Barone; Michael A. | Tensioning device for sporting racquets |
US5883166A (en) * | 1997-06-26 | 1999-03-16 | Jennings; Thomas C. | Liquid internal mold release agents for unsaturated polyester thermosetting molding compounds |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
JP4333676B2 (ja) | 1997-11-21 | 2009-09-16 | オムロン株式会社 | プログラム制御装置、プログラム制御方法、およびプログラム記録媒体 |
US6291514B1 (en) * | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
EP1137415A4 (en) * | 1998-12-07 | 2002-03-20 | Smithkline Beecham Corp | MYT1 KINASE INHIBITORS |
AU760964B2 (en) | 1998-12-31 | 2003-05-22 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy |
UA71971C2 (en) * | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
DE60136530D1 (de) | 2000-03-01 | 2008-12-24 | Janssen Pharmaceutica Nv | 2,4-disubstituierte thiazolyl derivate |
US7087608B2 (en) | 2000-03-03 | 2006-08-08 | Robert Charles Atkins | Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
US6586453B2 (en) * | 2000-04-03 | 2003-07-01 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
US6892245B1 (en) | 2000-09-22 | 2005-05-10 | Nortel Networks Limited | Management information base for a multi-domain network address translator |
JP2002185796A (ja) | 2000-12-11 | 2002-06-28 | Canon Inc | 画像読取処理システムおよび画像読取処理方法、並びに記録媒体 |
ITTO20010110A1 (it) * | 2001-02-08 | 2002-08-08 | Rotta Research Lab | Nuovi derivati benzamidinici dotati di attivita' anti-infiammatoria ed immunosoppressiva. |
GB0108606D0 (en) | 2001-04-05 | 2001-05-23 | Novartis Ag | Organic compounds |
EP1260876B1 (en) | 2001-05-25 | 2013-05-22 | Ricoh Company, Ltd. | A platen cover, image scanning device and image forming apparatus with the cover |
CA2452390A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating bone loss |
ATE330608T1 (de) | 2001-06-29 | 2006-07-15 | Ab Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
US20030091974A1 (en) | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
WO2003002106A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitions for treating allergic diseases |
WO2003004006A2 (en) | 2001-06-29 | 2003-01-16 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
US20050054617A1 (en) | 2001-06-29 | 2005-03-10 | Alain Moussy | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
CA2452361A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
WO2003004007A2 (en) | 2001-06-29 | 2003-01-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
EP1401414A2 (en) | 2001-06-29 | 2004-03-31 | AB Science | Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
CA2452368A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
JP2005507916A (ja) | 2001-09-20 | 2005-03-24 | アブ サイエンス | 細菌感染症を治療するための、強力で選択的かつ非毒性のc−kit阻害剤の使用方法 |
ATE401078T1 (de) | 2001-09-20 | 2008-08-15 | Ab Science | Die verwendung von c-kithemmern zur förderung des haarwuchses |
EP1427422A1 (en) | 2001-09-20 | 2004-06-16 | AB Science | Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases |
JP2003134307A (ja) | 2001-10-26 | 2003-05-09 | Canon Inc | 画像読取装置 |
US20030158199A1 (en) * | 2002-01-25 | 2003-08-21 | Kylix, B.V. | Novel compounds for inhibition of Tie-2 |
EP1467981A1 (en) | 2002-01-25 | 2004-10-20 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
CA2494695C (en) * | 2002-08-02 | 2011-04-05 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
US8153792B2 (en) | 2007-02-13 | 2012-04-10 | Ab Science | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors |
-
2003
- 2003-07-31 CA CA2494695A patent/CA2494695C/en not_active Expired - Lifetime
- 2003-07-31 ES ES03784419T patent/ES2294344T3/es not_active Expired - Lifetime
- 2003-07-31 AT AT03784419T patent/ATE375342T1/de active
- 2003-07-31 CN CNB03823145XA patent/CN100491374C/zh not_active Expired - Lifetime
- 2003-07-31 KR KR1020057001919A patent/KR101036866B1/ko active IP Right Grant
- 2003-07-31 NZ NZ538490A patent/NZ538490A/en not_active IP Right Cessation
- 2003-07-31 US US10/523,018 patent/US20050239852A1/en not_active Abandoned
- 2003-07-31 BR BRPI0313165A patent/BRPI0313165B8/pt active IP Right Grant
- 2003-07-31 JP JP2004527232A patent/JP4726486B2/ja not_active Expired - Lifetime
- 2003-07-31 DE DE60316810T patent/DE60316810T2/de not_active Expired - Lifetime
- 2003-07-31 EP EP03784419A patent/EP1525200B1/en not_active Expired - Lifetime
- 2003-07-31 DK DK03784419T patent/DK1525200T3/da active
- 2003-07-31 WO PCT/IB2003/003685 patent/WO2004014903A1/en active IP Right Grant
- 2003-07-31 MX MXPA05001277A patent/MXPA05001277A/es active IP Right Grant
- 2003-07-31 PT PT03784419T patent/PT1525200E/pt unknown
- 2003-07-31 IL IL16652803A patent/IL166528A0/xx active IP Right Grant
- 2003-08-01 US US10/632,101 patent/US7423055B2/en not_active Expired - Lifetime
-
2005
- 2005-02-15 ZA ZA2005/01331A patent/ZA200501331B/en unknown
- 2005-03-02 NO NO20051115A patent/NO330608B1/no not_active IP Right Cessation
-
2006
- 2006-03-07 HK HK06102936.7A patent/HK1084382A1/xx not_active IP Right Cessation
-
2007
- 2007-07-18 US US11/779,633 patent/US20080255141A1/en not_active Abandoned
- 2007-11-27 CY CY20071101517T patent/CY1107036T1/el unknown
-
2011
- 2011-01-28 US US13/015,664 patent/US8835435B2/en not_active Expired - Lifetime
-
2013
- 2013-11-26 US US14/089,946 patent/US8993573B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05001277A (es) | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. | |
BRPI0415467A (pt) | compostos de 2-aminoariloxazol para o tratamento de doenças | |
UA95071C2 (ru) | Замещенные производные оксазола и их применение как ингибиторов тирозинкиназы | |
NO20063861L (no) | 2-(3-substituert aryl)amin-4-arylthiazoler som tyrosinkinasehemmere | |
WO2006064375A2 (en) | Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases | |
NO20075627L (no) | Inhibitorer av cytosolisk fosfolipase A2 | |
ATE381332T1 (de) | Tyrosinkinase-hemmer | |
CY1110663T1 (el) | 2-αμινοαρυλοξαζολικες ενωσεις ως παρεμποδιστες κινασων της τυροσινης | |
WO2004089286A3 (en) | Novel compounds and compositions as protein kinase inhibitors | |
DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
NO20082508L (no) | Aminopyrimidiner anvendelige som kinaseinhibitorer | |
MXPA05013224A (es) | Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas. | |
ATE450530T1 (de) | Zusammensetzungen zur verwendung als protein- kinase-inhibitoren | |
ATE368457T1 (de) | Tyrosinkinase inhibitoren | |
MXPA05005223A (es) | Diaminotriazoles utiles como inhibidores de proteinas cinasas. | |
WO2008002571A3 (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
IL192557A (en) | Imidazole derivatives are conserved and used as ptpase inhibitors | |
ATE334693T1 (de) | Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten | |
ATE494008T1 (de) | Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen | |
JO2724B1 (en) | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors | |
EP1597234A4 (en) | NEW COMPOUNDS | |
CU20070222A7 (es) | Derivados de oxazol sustituidos y su uso como inhibidores de tirosina quinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |